This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
This study sought to examine temporal trends in the clinical characteristics and inhospital occurrence of adverse outcomes of IE.Methods and ResultsUsing the Japan nationwide administrative database, we identified patients with IE in Japan from 2016 to 2021. per 100 000 population in 2021. A total of 17 407 patients with IE (37.8%
Despite proven benefits in reducing morbidity and mortality, many heartfailure (HF) patients do not receive optimal guideline-directed medical therapy (GDMT). The 2021 European Society of Cardiology guidelines recommend guideline-directed medical therapy (GDMT) for patients with HF with reduced ejection fraction (HFrEF).
Heartfailure (HF) is a highly prevalent long-term condition, with variation in services and resources across the UK. This report provides findings from a cross-sectional survey of community HF services in the UK between September 2021 and February 2022. Eighty-five responses describing community HF services were received.
Heartfailure (HF) is a significant problem in the UK with variation in services across the country. Here we describe the findings from a cross-sectional survey of HF services in the UK performed between September 2021 and February 2022. The clinical lead in 82% of hospitals was a cardiologist with specialist interest in HF.
Discontinuation and reinitiation of mineralocorticoid receptor antagonists (MRA) in patients with heartfailure and reduced ejection fraction (HFrEF). BMI, body mass index; eGFR, estimated glomerular filtration rate; NYHA, New York Heart Association.
Heartfailure with reduced ejection fraction (HFrEF) survey endorsed by the Council for Cardiology Practice and the HeartFailure Association of the European Society of Cardiology (ESC).
Aim The value of disease-modifying therapies (such as tafamidis) in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) and severe heartfailure symptoms has been debated. After 30 months of treatment, patients could join an ongoing LTE study to receive open-label tafamidis.
Integration of palliative care in the 2021 ESC and the 2022 AHA/ACC/HFSA heartfailure guidelines. ACC, American College of Cardiology; AHA, American Heart Association; ESC, European Society of Cardiology; HF, heartfailure; HFSA, HeartFailure Society of America; LD, limited; R, randomized.
Abstract Document Reviewers: Rudolf A. de Boer (CPG Review Co-ordinator) (Netherlands), P. Christian Schulze (CPG Review Co-ordinator) (Germany), Elena Arbelo (Spain), Jozef Bartunek (Belgium), Johann Bauersachs (Germany), Michael A.
From 2021 to 2023, there was an increase in prescription rates of a sodium-glucose cotransporter-2 inhibitor (SGLT2i) for patients with heartfailure and a left ventricular ejection fraction (LVEF) greater than 40 percent, according to a study published online Nov. 16 to 18 in Chicago.
Methods Using the publicly accessible Centers for Medicare and Medicaid Services Medicare Part D database and the Open Payments Database, this study assessed associations between industry-sponsored meal payments to physician prescribers and total amounts of Medicare claims and spending for sacubitril/valsartan between 2015 and 2021.
Research design and methods All patients with diabetes and CAD undergoing a coronary angiography between 2010 and 2021 according to the Swedish Angiography and Angioplasty Registry were included. Information on GLD (dispended 6 months before or after coronary angiography) was collected from the Swedish Prescribed Drug Registry.
Current Role of Digoxin in HeartFailure as Per Guidelines and DIGIT-HF trial of Digitoxin Use of digoxin in heartfailure has come down markedly over the past decades due to concerns of toxicity and availability of more effective medications. Eur Heart J. 2021 Sep 21;42(36):3599-3726. Eur J Heart Fail.
2021 May 21;23(5):740-747. However, advanced heartfailure therapy never means it can be achieved only by state-of-the-art technology. Cardiac failure management remains basically disciplined medical management and a holistic approach to improve the quality of life. Heart Rhythm. Epub 2021 Jul 29.
AimsTo assess the barriers to guideline-directed medical therapy (GDMT) use in heartfailure (HF), diagnostic workup and general knowledge about HF among physicians in Sweden.MethodsA survey about the management of HF was sent to 828 Swedish physicians including general practitioners (GPs) and specialists during 2021–2022.
Background: The heartfailure (HF) virtual consultation (VC) is an eHealth tool for delivery of peer-to-peer specialist advice to general practitioners (GPs) to discuss HF diagnosis/management. Reults: Between 2015 and 2021, 1681 VC cases were discussed. The majority of cases were discussed from remote areas (75%).
Introduction Heartfailure (HF) incidence is increasing in older adults with high hospitalisation and mortality rates. Results Data were collected in April 2012 to January 2014 and in June 2021 to December 2022. Treatment is complicated by side effects and comorbidities. Statistical significance is determined at p<0.05.
The following are key points to remember from a 2024 ACC Expert Consensus Decision Pathway for treatment of heartfailure with reduced ejection fraction (HFrEF), an update to the 2021 document.
Objectives (1) Develop a programme theory of why, for whom and in what contexts integrated palliative care (PC) and heartfailure (HF) services work/do not work; (2) use the programme theory to co-produce with stakeholders, intervention strategies to inform best practice and future research.
Knowledge and application of European Society of Cardiology/HeartFailure Association (ESC/HFA) guidelines in the management of advanced heartfailure (HF). Respondents were categorized into heartfailure cardiologists (HFCs), general cardiologists (GCs), and other participants (OPs).
BACKGROUND:The absence of practice standards in vasoactive agent usage for acute decompensated heartfailure has resulted in significant treatment variability across hospitals, potentially affecting patient outcomes. in 2021 (Ptrend<0.001). in 2021 or the proportion of phenotype-based utilization. in 2013 to 48.6%
Aims Heartfailure (HF) has a lower public profile compared with other serious health conditions, notably cancer. times that of the other conditions; annual cancer mortality is two times that caused by coronary heart disease (including HF) or dementia. times per million words (pmw), ‘dementia’ occurs 3.68
Cardiac amyloidosis is a heterogeneous disease that results from the accumulation of abnormal proteins within the heart, impairing its ability to pump blood. Over time, the build-up of these proteins causes the heart muscle to stiffen, eventually leading to heartfailure, which can have dire outcomes if not found early.
Abstract Aims The COVID-19 pandemic disrupted healthcare systems and possibly impacted the management of heartfailure (HF). This study examined the impact of the pandemic on HF hospitalization activities, outcomes, and costs in Victoria, Australia. Data were analysed using descriptive analysis and interrupted time series analysis.
Clinical presentation, shock severity and mortality in patients with de novo versus acute-on-chronic heartfailure-related cardiogenic shock. ACHF-CS, acute-on-chronic failure-related cardiogenic shock; CI, confidence interval; DNHF-CS, de novo heartfailure-related cardiogenic shock; HR, hazard ratio.
By 2021 almost half of patients younger than 60 years were receiving TAVR rather than SAVR. Secondary outcomes included rates of reoperation, infective endocarditis, stroke, and hospital admissions for heartfailure. The research team followed these patients for a median time of 2.4 years after TAVR and 4.9 for SAVR vs. 0.4%
Background:The prevalence of risk factors for heartfailure and outcomes varies across racial and ethnic groups. Despite this variation, treatment guidelines for heartfailure are standardized, potentially overlooking the unique needs and responses of minority populations.
Background This review aimed to compare the relative effectiveness of different exercise-based cardiac rehabilitation (ExCR) delivery modes (centre-based, home-based, hybrid and technology-enabled ExCR) on key heartfailure (HF) outcomes: exercise capacity, health-related quality of life (HRQoL), HF-related hospitalisation and HF-related mortality.
Objective To evaluate stress, depression and quality of life among community-dwelling patients with heartfailure (HF) and evaluate their effect on perceived medication adherence in a socioeconomically challenged setting.
Methods A total of 469 consecutive patients undergoing TAVI between 2015 and 2021 were enrolled. The primary clinical outcome measure was all-cause mortality and heartfailure hospitalisation 1 year after TAVI. versus 2.0%, respectively (p<0.01), and that of heartfailure hospitalisation was 10.7% 95% CI 2.21
Background Patients with heartfailure exhibiting low systolic blood pressure (SBP) have a poor prognosis. Methods We analysed data from a multicentre retrospective study, including patients who initiated sacubitril/valsartan between August 2020 and August 2021.
Angiogram in 2021 was normal. Most patients with heartfailure with reduced ejection fraction and left bundle branch block with a QRS over 130 ms should get one. Old records still had not appeared. Around 1015 we were able to access Care everywhere and this showed that he has a non-ischemic cardiomyopathy with EF of 15%.
The Award will refer to articles published in 2021 and 2022. The Award will be given to the Brazilian authors of the best Original Article published in the ABC Cardiol and IJCS journals for the years 2021 and 2022, and to Brazilian authors of the best Original Article published in the ABC Imagem and ABC HF journals in 2022.
years]) admitted to the China Chest Pain Center Database between 2016 and 2021. Hierarchical clustering of 15 medical conditions was performed to derive multimorbidity patterns. The primary outcome was a composite of inhospital adverse events.
This certification is known to be one of the harder ones, with a pass rate of 88% in 2021 , so don’t procrastinate studying. HeartFailure and Cardiomyopathy 19% Valvular Disease 15% Pericardial Disease 3% Congenital Heart Disease 3% Vascular Diseases 5% Systemic Hypertension and Hypotension 8.5%
Background:The STRACK project aims to improve post-stroke patient management and the transition from acute to primary care thanks to improvements in patient pathways and monitoring cardiovascular risk factors: heartfailure, diabetes, atrial fibrillation, dyslipidemia and hypertension.
There will be an award for the most cited national manuscript in the last two years, namely: the most cited article published in 2021 and 2022 in 2023, for the journals ABC Cardiol and IJCS; and the most accessed in 2023 for the journals ABC Imagem and ABC HF. for enrollment in courses at the Heart University.
Methods We included adult patients who had an index admission with AF to Latakia's tertiary center between July 2021 and November 2023. 95% CI: 1.62.7), and congestive heartfailure (CCF) (HR: 2.1, This study assessed the rate, predictors, and trends of 6-month readmission after index admission for AF in Syria. 95% CI: 1.42.6).
Following publication of the 2021 stroke prevention guidelines, GLP1RA use increased in 2022 to 9%. Background:The current AHA stroke prevention guidelines give Class 1 recommendations that patients with AIS and diabetes should receive glucose-lowering agents with cardiovascular benefit to reduce risk of MACE.
The device is a patented 3-lead, 2-channel wireless continuous ECG wearable device that allows physicians the ability to address and assess sleep and heart health remotely. American Heart Association (2021). Sleep apnea worsens heart disease, yet often untreated. David's Medical Center. Retrieved from [link] 2.
The Cardiovascular Disease Maintenance of Certification Exam can be difficult, with a pass rate in 2021 of 88%. HeartFailure and Cardiomyopathy 19% Valvular Disease 15% Pericardial Disease 3% Congenital Heart Disease 3% Vascular Diseases 5% Systemic Hypertension and Hypotension 8.5% What does the exam cover?
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
45 
Let's personalize your content